|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
By Industry | By Industry Segment | By Services and Suppliers
| By Location
| By Hotbed |
Profile Search
|
Lexigen Pharmaceuticals Corp.
125 Hartwell Avenue
Lexington
Massachusetts
02421
U.S.A.
Phone:
781-861-5300
Fax:
781-861-5301
|
Lexigen Pharmaceuticals Corp. is a leader in the creative development of genetically engineered proteins. The strategy of Lexigen Pharmaceuticals Corp. is to develop unique treatments for cancer and other serious, life-threatening diseases, and at the same time to develop broad technology platforms that will lead to new therapies.
Lexigen has two novel immunocytokines in clinical development. These antibody-cytokine fusion proteins target the immune system to specific cell types. Lexigen is developing the immunocytokines as cancer treatments, and simultaneously developing the immunocytokine concept as a broad, proprietary technology base.
Lexigen is an associate of Merck KGaA, Darmstadt, Germany, a multi-national pharmaceutical company with over 30,000 employees and annual revenues of approximately eight billion dollars. Thus, Lexigen combines the flexibility and creativity of a star-up biotech environment, with the financial stability, global presence, and commercial expertise of a large pharmaceutical company.
Last Updated 9-21-01
Email:
info@lexigenpharm.com
Ownership:
Private
Web Site:
Lexigen Pharmaceuticals Corp.
Employees:
Symbol:
|
|
|
 |
|
|
|
|
|
|
|
|
|